Skip to content

Patient experience and advocacy

TL;DR — A 2026-08-29 PubMed E-utilities search retrieved 23 exact-phrase HHD records with qualitative/patient-experience terms; screening found 0 studies recruiting patients explicitly by an HHD diagnosis to study their experience. This page therefore triangulates hypertension, difficult-to-treat hypertension and HFpEF without pretending they are identical. The central tension is invisible risk versus visible treatment burden: BP and early remodeling may feel like nothing, while daily pills, monitoring, side effects, costs and appointments are immediate. A 27-study qualitative synthesis found knowledge, beliefs, behavior and social support facilitate adherence, while low medication literacy, weak perceived benefit, restricted access and unintentional nonadherence impede it (Zhou 2024, PMID 38549805). Rural and low-resource studies show that transport, medicine stock, device availability and clinic capacity are not “patient noncompliance” (Khatib 2014, PMID 24454721; Oyando 2025, PMID 41270024). Once HF develops, breathlessness, fatigue, edema and loss of function reshape daily life for patients and caregivers (Niklasson 2022, PMID 35081667).

1. Evidence boundary

Evidence source What it contributes What it cannot establish
Hypertension qualitative study Illness beliefs, monitoring, medication and access Imaging-defined HHD experience
Difficult-to-treat hypertension interview Treatment burden and procedural hopes Typical controlled-hypertension experience
HFpEF qualitative study Symptom, function and caregiver burden Etiologic attribution to hypertension
Adherence meta-synthesis Recurring cross-setting mechanisms Prevalence of each barrier
Patient organization Public education and advocacy priorities Representative epidemiology

No private social-media testimony was collected. Public organizational material is paraphrased; no private individual is identified.

2. “Silent” disease and uncertain benefit

People are asked to treat a number they may not feel in order to prevent events years later. Symptom-based illness models can therefore conflict with chronic preventive treatment.

Interviews with Middle Eastern refugees and migrants in Australia found that beliefs about symptoms, causes, medication and trust in healthcare encounters shaped adherence (Shahin 2021, PMID 35480607).

Among Indigenous Akha participants in Northern Thailand, sustained home-monitoring barriers included symptom-based recognition, fear of lifelong medication, work/livelihood priorities, limited information and logistical access (Gantagad 2025, PMID 41189998).

Lived inference Clinical correction
“I feel well, so pressure is controlled” Symptoms do not measure BP
“The medicine made the illness visible” Side effects are real even when risk is silent
“One good reading means cure” Pressure varies and treatment suppresses rather than erases susceptibility
“One high reading means emergency” Context, repeat measurement and organ injury matter

3. Diagnosis as disruption

Qualitative research across Mozambique, Nepal and Peru described chronic hypertension/diabetes as disrupting daily roles, family dynamics and finances, with adaptations shaped by gender and weak health systems (Pesantes 2020, PMID 31596656).

Women interviewed in Nepal described illness perception, medication adherence, healthcare dissatisfaction, financial barriers and family support as connected rather than separate domains (Kc 2023, PMID 36974856).

Disruption Adaptive work
New chronic identity Integrating treatment without becoming defined by disease
Food changes Negotiating household and cultural diet
Monitoring Learning technique and interpreting variation
Appointments Transport, waiting and work absence
Medication Routines, refills, side effects and cost
Family roles Support can help or produce surveillance/conflict

4. Medication burden is multidimensional

A 27-study qualitative meta-integration identified two broad findings: knowledge/belief/behavior and social support facilitate adherence; poor medication literacy, role difficulty, low perceived benefit, limited resources and unintentional lapses impede it (Zhou 2024, PMID 38549805).

The earlier global review included 25 qualitative and 44 quantitative studies; health-system barriers were prominent for both patients and providers, while lack of knowledge dominated patient awareness barriers (Khatib 2014, PMID 24454721).

Domain Examples reported across studies
Patient Beliefs, memory, competing priorities, fear, self-efficacy
Therapy Side effects, complexity, perceived inefficacy
Social Family support, norms, peer information
Economic Medication, tests, transport, lost work time
Health system Stock-outs, waiting, short visits, device shortages
Relationship Trust, explanation, continuity and shared goals

U.S. interviews among adults with CHD risk factors similarly located adherence across self-efficacy, social support, cost, side effects, schedules and healthcare access (Mondesir 2019, PMID 31819383).

5. Access is part of the treatment mechanism

Rural coastal Kenya interviews/focus groups identified information barriers, limited perceived facility capacity, poor fit for asymptomatic screening and access problems across the care cascade (Oyando 2025, PMID 41270024).

In northern Tanzania, patient and clinician interviews identified knowledge, chronicity, communication, family support, fear and structural barriers to follow-up after emergency-department detection (Galson 2023, PMID 36608026).

Among couples managing HIV plus hypertension/diabetes in Malawi, CMD care was compared unfavorably with free, reliable HIV services; medication shortages, test/treatment cost, transport, waiting and broken/unavailable equipment were recurrent barriers (Ogugu 2024, PMID 38678232).

These findings reclassify many “adherence failures” as delivery failures.

6. Geographic synthesis

Setting Reported themes Source
Southern Ethiopia Six themes spanning management, care and context in 14 interviews Endrias 2024, PMID 39702319
Rural coastal Kenya Information, screening capacity, acceptability and access Oyando 2025, PMID 41270024
East Africa, 34 studies Literacy/risk perception, trust, inconsistent delivery, finances and norms Perry 2025, PMID 41414744
Nepal Affordability, resource scarcity, communication, waits and adherence Dhungana 2021, PMID 34708082
Southeastern Iran Family, inexpensive medicines, insurance, team support and media as facilitators Ghaderi Nasab 2024, PMID 39628801
Australia migrants/refugees Symptom/cause beliefs, medicine practices and trust Shahin 2021, PMID 35480607

7. Monitoring: agency and anxiety

Home BP can make an invisible exposure visible and support titration. It can also generate anxiety, selective measurement or abandonment when numbers vary without a plan.

Individual-patient meta-analysis found self-monitoring lowered clinic systolic BP 3.2 mm Hg at 12 months overall, but monitoring alone had no clear effect; benefit depended on co-intervention (Tucker 2017, PMID 28926573).

HOME BP paired monitoring with feedback and guided self-management, producing approximately 3.4-mm Hg better one-year systolic control than usual care (McManus 2021, PMID 33468518).

A smartphone-coaching trial found an adjusted systolic difference of −2.0 mm Hg (95% CI −4.9 to 0.8), showing that technology and a monitor are not automatically effective (Persell 2020, PMID 32119093).

8. Difficult-to-treat hypertension

Interviews with 12 Australian adults with severe difficult-to-treat hypertension found four themes: diagnosis/monitoring, quality-of-life impact, management experience and awareness/perceptions of renal denervation. Participants had lived with hypertension a mean 22 years (Hill 2026, PMID 42321603).

This group’s procedural interest should be interpreted alongside the modest sham-adjusted BP evidence and uncertainty about cardiovascular outcomes (Vukadinović 2024, PMID 39355923).

Hope Communication requirement
Fewer medications Not guaranteed
More stable BP Report expected average and variability
Protection from events Outcome evidence remains incomplete
One-time cure Ongoing monitoring and treatment may remain necessary

9. Transition to symptomatic HF

Forty HF interview participants described difficulty with inclines, stairs, distance, speed, standing, carrying and lifting, driven by dyspnea, fatigue and edema. Adaptations included rest, slowing and avoidance (Niklasson 2022, PMID 35081667).

In HFpEF, interviews with 19 patients and 17 caregivers found quality-of-life impact, new informal-caregiving roles and perceived value of multidisciplinary care; quantitative PROMs did not capture all interview-reported burden (Rubio 2025, PMID 40649089).

A qualitative meta-study found HFpEF difficult for clinicians to diagnose and for patients/caregivers to understand, with inadequate support contributing to a “cycle of decline” and loss of control (Frost 2025, PMID 40625643).

10. Caregiver and family roles

Family can support reminders, transport, diet and interpretation, but also absorbs financial, time and emotional burden. Family support facilitated adherence in Nepalese women and Iranian participants; HFpEF created new informal-caregiver roles (Kc 2023, PMID 36974856; Ghaderi Nasab 2024, PMID 39628801; Rubio 2025, PMID 40649089).

Caregiver involvement should therefore be offered, not assumed, and should preserve patient autonomy.

11. Advocacy organizations verified this session

Organization Scope Verified public role
World Hypertension League Global network Hypertension prevention/control and World Hypertension Day (https://www.whleague.org/, accessed 2026-08-29)
Resolve to Save Lives Global public health Hypertension-control programs and cardiovascular prevention (https://resolvetosavelives.org/, accessed 2026-08-29)
Hypertension Canada Canada Professional/public hypertension education and guidance (https://hypertension.ca/, accessed 2026-08-29)
Million Hearts United States Federal initiative for cardiovascular-event prevention and BP control (https://millionhearts.hhs.gov/, accessed 2026-08-29)

These are advocacy/implementation sources, not representative patient-experience samples.

12. Patient-centered outcome set for HHD research

Domain Candidate measure
Treatment burden Pills, dosing, monitoring, visits, laboratory checks
Side effects Symptom-specific patient report
Understanding Illness and treatment model
Access Travel, wait, cost, stock continuity
Function Walking, stairs, work and household roles
Symptoms Dyspnea, fatigue, edema, palpitations, dizziness
Emotional impact Worry, uncertainty, loss of control
Caregiver impact Time, role change and support needs

BP and LV mass alone do not capture whether a prevention strategy is livable.

Open questions

  • What is distinctive about living with imaging-defined asymptomatic HHD versus hypertension alone? (Nwabuo 2020, PMID 32016791)
  • How do monitoring and biomarker staging affect anxiety, agency and adherence? (Sharp 2026, PMID 41771092; Tucker 2017, PMID 28926573)
  • Which treatment-burden outcomes should accompany intensive-control and device trials? (Hill 2026, PMID 42321603; Vukadinović 2024, PMID 39355923)
  • Can health-system interventions reduce both BP and inequity in clinical HHD outcomes? (Sun 2022, PMID 35500594; Siedner 2025, PMID 40888742)

References

  1. Zhou X, et al. Barriers and Facilitators of Medication Adherence in Hypertension Patients: A Meta-Integration of Qualitative Research. J Patient Exp. 2024;11:23743735241241176. PMID 38549805
  2. Khatib R, et al. Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-analysis of qualitative and quantitative studies. PLoS One. 2014;9:e84238. PMID 24454721
  3. Oyando R, et al. Access to hypertension services and health-seeking experiences in rural Coastal Kenya: A qualitative study. PLOS Glob Public Health. 2025;5:e0004324. PMID 41270024
  4. Niklasson A, et al. Living with heart failure: patient experiences and implications for physical activity and daily living. ESC Heart Fail. 2022;9:1206-1215. PMID 35081667
  5. Shahin W, et al. A qualitative exploration of the impact of knowledge and perceptions about hypertension in medication adherence in Middle Eastern refugees and migrants. Explor Res Clin Soc Pharm. 2021;3:100038. PMID 35480607
  6. Gantagad T, et al. Cultural and Contextual Barriers to Sustained Home Blood Pressure Monitoring Practices Among Indigenous People in Northern Thailand: A Qualitative Study. Int J Community Based Nurs Midwifery. 2025;13:274-285. PMID 41189998
  7. Pesantes MA, et al. Disruption, changes, and adaptation: Experiences with chronic conditions in Mozambique, Nepal and Peru. Glob Public Health. 2020;15:372-383. PMID 31596656
  8. Kc D, et al. Illness Perception of Women Living with Hypertensive Condition: A Qualitative Study. J Nepal Health Res Counc. 2023;20:677-682. PMID 36974856
  9. Mondesir FL, et al. Patient Perspectives on Factors Influencing Medication Adherence Among People with Coronary Heart Disease (CHD) and CHD Risk Factors. Patient Prefer Adherence. 2019;13:2017-2027. PMID 31819383
  10. Galson SW, et al. Hypertension in an Emergency Department Population in Moshi, Tanzania; A Qualitative Study of Barriers to Hypertension Control. PLoS One. 2023;18:e0279377. PMID 36608026
  11. Ogugu EG, et al. Barriers to accessing care for cardiometabolic disorders in Malawi: partners as a source of resilience for people living with HIV. Int J Equity Health. 2024;23:83. PMID 38678232
  12. Endrias EE, et al. Exploring experiences and perspectives of patients on hypertension management in Southern Ethiopia: a phenomenological study. BMC Health Serv Res. 2024;24:1625. PMID 39702319
  13. Perry M, et al. A scoping review of qualitative studies examining the factors influencing hypertension treatment adherence in East Africa. J Biosoc Sci. 2025;57:649-670. PMID 41414744
  14. Dhungana RR, et al. Barriers, Enablers and Strategies for the Treatment and Control of Hypertension in Nepal: A Systematic Review. Front Cardiovasc Med. 2021;8:716080. PMID 34708082
  15. Ghaderi Nasab Z, et al. Facilitators of medication adherence in patients with hypertension: a qualitative study. Front Public Health. 2024;12:1372698. PMID 39628801
  16. Tucker KL, et al. Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis. PLoS Med. 2017;14:e1002389. PMID 28926573
  17. McManus RJ, et al. Home and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hypertension: randomised controlled trial. BMJ. 2021;372:m4858. PMID 33468518
  18. Persell SD, et al. Effect of Home Blood Pressure Monitoring via a Smartphone Hypertension Coaching Application or Tracking Application on Adults With Uncontrolled Hypertension: A Randomized Clinical Trial. JAMA Netw Open. 2020;3:e200255. PMID 32119093
  19. Hill M, et al. Qualitative insights into the experiences and goals of people living with severe difficult-to-treat hypertension in Australia. BMC Cardiovasc Disord. 2026;26. PMID 42321603
  20. Vukadinović D, et al. Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis. Circulation. 2024;150:1599-1611. PMID 39355923
  21. Rubio R, et al. Quality of Life and Experience of Patients with Heart Failure with Preserved Ejection Fraction and Their Caregivers. J Clin Med. 2025;14. PMID 40649089
  22. Frost J, et al. Understanding the self-management experiences of people with heart failure with preserved ejection fraction (HFpEF), their caregivers and the health care professionals who support them: Systematic review and qualitative meta-study. Br J Card Nurs. 2025;20:1-30. PMID 40625643
  23. Nwabuo CC, et al. Pathophysiology of Hypertensive Heart Disease: Beyond Left Ventricular Hypertrophy. Curr Hypertens Rep. 2020;22:11. PMID 32016791
  24. Sharp A, et al. Role of natriuretic peptides and cardiac troponins in staging hypertensive heart disease: the REMODEL study. Eur J Heart Fail. 2026. PMID 41771092
  25. Sun Y, et al. A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial. Lancet. 2022;399:1964-1975. PMID 35500594
  26. Siedner MJ, et al. Home-Based Care for Hypertension in Rural South Africa. N Engl J Med. 2025;393:1304-1314. PMID 40888742